-
Article
Open AccessAuthor Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
-
Article
Open AccessGemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, p...
-
Article
Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
Defects in pathways governing genomic fidelity have been linked to improved response to immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause hypermutation, yet how diverse mutations...
-
Article
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB) treatment, but current decision-making procedures have limited accuracy. In this study, we developed a machine learning model...
-
Article
The association between tumor mutational burden and prognosis is dependent on treatment context
In multiple cancer types, high tumor mutational burden (TMB) is associated with longer survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with survival outside of the imm...
-
Article
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced cancer, but the determinants of response remain poorly understood. Here we report differential effects of mutations in the homo...
-
Article
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
Anti-tumor immunity is driven by self versus non-self discrimination. Many immunotherapeutic approaches to cancer have taken advantage of tumor neoantigens derived from somatic mutations. Here, we demonstrate ...
-
Article
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor mutational burden (TMB) ma...
-
Article
Open AccessDissecting microsatellite instability in colorectal cancer: one size does not fit all
Microsatellite instability (MSI) marks distinct subsets of tumors in many cancer types and is caused by mutations in genes required for mismatch repair. A recent report analyses the molecular foundations of MS...
-
Chapter
Combining Radiotherapy and Immunotherapy: Emerging Preclinical Observations of Lymphocyte Costimulatory and Inhibitory Receptor Modulation
A greater understanding of immune system biology has translated into more effective cancer immunotherapeutics. This has prompted exploration of the combination of these agents with other cancer treatments such...
-
Article
Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells
The transcription factor Foxp3 is essential for the function of regulatory T cells (Treg cells). Rudensky and colleagues show binding of Foxp3 poises target genes for repression and, after activation of Treg cell...
-
Article
Transcription factor Foxp3 and its protein partners form a complex regulatory network
The transcription factor Foxp3 is essential for the function of regulatory T cells. Rudensky and colleagues show Foxp3 participates in large protein complexes that regulate gene expression of many of these com...
-
Article
Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells
Here we investigated the potential role of bone-resorbing osteoclasts in homeostasis and stress-induced mobilization of hematopoietic progenitors. Different stress situations induced activity of osteoclasts (O...
